CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease

Moeko Noguchi-Shinohara, Takahiko Tokuda, Mitsuhiro Yoshita, Takashi Kasai, Kenjiro Ono, Masanori Nakagawa, Omar Ali El-Agnaf, Masahito Yamada

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Dementia with Lewy bodies (DLB) is characterized by widespread depositions of α-synuclein, which are described as Lewy bodies. Recently, it was shown that neuronal cells in culture constitutively release α-synuclein into the culture medium and that α-synuclein is normally present in human cerebrospinal fluid (CSF). The aim of the present study was to evaluate the diagnostic value of CSF α-synuclein levels in discriminating DLB from Alzheimer's disease (AD). α-Synuclein was measured in CSF from 16 patients with DLB and 21 patients with AD. Iodine-123 metaiodobenzylguanidine cardiac scintigraphy was also performed to assess Lewy body pathology. CSF α-synuclein levels did not differ significantly between DLB and AD patients. However, the duration of illness was associated with lower α-synuclein levels (p < 0.05) in DLB, while no such association was found in AD. The present data show CSF α-synuclein levels are not sensitive diagnostic markers to discriminate DLB from AD. However, the lower α-synuclein levels in DLB patients with longer duration suggest a reduction in CSF α-synuclein in association with increased severity of α-synucleinopathy in the brain.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalBrain Research
Volume1251
DOIs
Publication statusPublished - 28 Jan 2009
Externally publishedYes

Fingerprint

Synucleins
Lewy Body Disease
Cerebrospinal Fluid
Dementia
Alzheimer Disease
Lewy Bodies
Radionuclide Imaging
Iodine
Culture Media
Cell Culture Techniques

Keywords

  • Alpha-synuclein
  • Dementia with Lewy bodies
  • Parkinson's disease
  • Parkinsonism

ASJC Scopus subject areas

  • Neuroscience(all)
  • Molecular Biology
  • Developmental Biology
  • Clinical Neurology

Cite this

Noguchi-Shinohara, M., Tokuda, T., Yoshita, M., Kasai, T., Ono, K., Nakagawa, M., ... Yamada, M. (2009). CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Research, 1251, 1-6. https://doi.org/10.1016/j.brainres.2008.11.055

CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. / Noguchi-Shinohara, Moeko; Tokuda, Takahiko; Yoshita, Mitsuhiro; Kasai, Takashi; Ono, Kenjiro; Nakagawa, Masanori; Ali El-Agnaf, Omar; Yamada, Masahito.

In: Brain Research, Vol. 1251, 28.01.2009, p. 1-6.

Research output: Contribution to journalArticle

Noguchi-Shinohara, M, Tokuda, T, Yoshita, M, Kasai, T, Ono, K, Nakagawa, M, Ali El-Agnaf, O & Yamada, M 2009, 'CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease', Brain Research, vol. 1251, pp. 1-6. https://doi.org/10.1016/j.brainres.2008.11.055
Noguchi-Shinohara M, Tokuda T, Yoshita M, Kasai T, Ono K, Nakagawa M et al. CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Research. 2009 Jan 28;1251:1-6. https://doi.org/10.1016/j.brainres.2008.11.055
Noguchi-Shinohara, Moeko ; Tokuda, Takahiko ; Yoshita, Mitsuhiro ; Kasai, Takashi ; Ono, Kenjiro ; Nakagawa, Masanori ; Ali El-Agnaf, Omar ; Yamada, Masahito. / CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. In: Brain Research. 2009 ; Vol. 1251. pp. 1-6.
@article{ed915ff24dbb45728bf37c3746ff049e,
title = "CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease",
abstract = "Dementia with Lewy bodies (DLB) is characterized by widespread depositions of α-synuclein, which are described as Lewy bodies. Recently, it was shown that neuronal cells in culture constitutively release α-synuclein into the culture medium and that α-synuclein is normally present in human cerebrospinal fluid (CSF). The aim of the present study was to evaluate the diagnostic value of CSF α-synuclein levels in discriminating DLB from Alzheimer's disease (AD). α-Synuclein was measured in CSF from 16 patients with DLB and 21 patients with AD. Iodine-123 metaiodobenzylguanidine cardiac scintigraphy was also performed to assess Lewy body pathology. CSF α-synuclein levels did not differ significantly between DLB and AD patients. However, the duration of illness was associated with lower α-synuclein levels (p < 0.05) in DLB, while no such association was found in AD. The present data show CSF α-synuclein levels are not sensitive diagnostic markers to discriminate DLB from AD. However, the lower α-synuclein levels in DLB patients with longer duration suggest a reduction in CSF α-synuclein in association with increased severity of α-synucleinopathy in the brain.",
keywords = "Alpha-synuclein, Dementia with Lewy bodies, Parkinson's disease, Parkinsonism",
author = "Moeko Noguchi-Shinohara and Takahiko Tokuda and Mitsuhiro Yoshita and Takashi Kasai and Kenjiro Ono and Masanori Nakagawa and {Ali El-Agnaf}, Omar and Masahito Yamada",
year = "2009",
month = "1",
day = "28",
doi = "10.1016/j.brainres.2008.11.055",
language = "English",
volume = "1251",
pages = "1--6",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",

}

TY - JOUR

T1 - CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease

AU - Noguchi-Shinohara, Moeko

AU - Tokuda, Takahiko

AU - Yoshita, Mitsuhiro

AU - Kasai, Takashi

AU - Ono, Kenjiro

AU - Nakagawa, Masanori

AU - Ali El-Agnaf, Omar

AU - Yamada, Masahito

PY - 2009/1/28

Y1 - 2009/1/28

N2 - Dementia with Lewy bodies (DLB) is characterized by widespread depositions of α-synuclein, which are described as Lewy bodies. Recently, it was shown that neuronal cells in culture constitutively release α-synuclein into the culture medium and that α-synuclein is normally present in human cerebrospinal fluid (CSF). The aim of the present study was to evaluate the diagnostic value of CSF α-synuclein levels in discriminating DLB from Alzheimer's disease (AD). α-Synuclein was measured in CSF from 16 patients with DLB and 21 patients with AD. Iodine-123 metaiodobenzylguanidine cardiac scintigraphy was also performed to assess Lewy body pathology. CSF α-synuclein levels did not differ significantly between DLB and AD patients. However, the duration of illness was associated with lower α-synuclein levels (p < 0.05) in DLB, while no such association was found in AD. The present data show CSF α-synuclein levels are not sensitive diagnostic markers to discriminate DLB from AD. However, the lower α-synuclein levels in DLB patients with longer duration suggest a reduction in CSF α-synuclein in association with increased severity of α-synucleinopathy in the brain.

AB - Dementia with Lewy bodies (DLB) is characterized by widespread depositions of α-synuclein, which are described as Lewy bodies. Recently, it was shown that neuronal cells in culture constitutively release α-synuclein into the culture medium and that α-synuclein is normally present in human cerebrospinal fluid (CSF). The aim of the present study was to evaluate the diagnostic value of CSF α-synuclein levels in discriminating DLB from Alzheimer's disease (AD). α-Synuclein was measured in CSF from 16 patients with DLB and 21 patients with AD. Iodine-123 metaiodobenzylguanidine cardiac scintigraphy was also performed to assess Lewy body pathology. CSF α-synuclein levels did not differ significantly between DLB and AD patients. However, the duration of illness was associated with lower α-synuclein levels (p < 0.05) in DLB, while no such association was found in AD. The present data show CSF α-synuclein levels are not sensitive diagnostic markers to discriminate DLB from AD. However, the lower α-synuclein levels in DLB patients with longer duration suggest a reduction in CSF α-synuclein in association with increased severity of α-synucleinopathy in the brain.

KW - Alpha-synuclein

KW - Dementia with Lewy bodies

KW - Parkinson's disease

KW - Parkinsonism

UR - http://www.scopus.com/inward/record.url?scp=58149374375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149374375&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2008.11.055

DO - 10.1016/j.brainres.2008.11.055

M3 - Article

C2 - 19071095

AN - SCOPUS:58149374375

VL - 1251

SP - 1

EP - 6

JO - Brain Research

JF - Brain Research

SN - 0006-8993

ER -